GSA Capital Partners LLP Takes $871,000 Position in Scholar Rock Holding Corporation $SRRK

GSA Capital Partners LLP bought a new position in Scholar Rock Holding Corporation (NASDAQ:SRRK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 15,838 shares of the company’s stock, valued at approximately $871,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. E. Ohman J or Asset Management AB increased its holdings in Scholar Rock by 5.3% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 23,309 shares of the company’s stock valued at $1,282,000 after acquiring an additional 1,173 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Scholar Rock by 37.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 32,200 shares of the company’s stock valued at $1,771,000 after purchasing an additional 8,700 shares during the last quarter. StoneCrest Wealth Management Inc. boosted its holdings in shares of Scholar Rock by 11.1% during the 2nd quarter. StoneCrest Wealth Management Inc. now owns 78,780 shares of the company’s stock valued at $4,333,000 after purchasing an additional 7,866 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Scholar Rock by 20.8% during the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock valued at $77,000 after purchasing an additional 242 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Scholar Rock by 27.2% during the first quarter. Bank of America Corp DE now owns 1,336,632 shares of the company’s stock valued at $65,709,000 after purchasing an additional 286,126 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SRRK shares. Citigroup boosted their target price on Scholar Rock from $58.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. BMO Capital Markets restated an “outperform” rating and set a $76.00 price target on shares of Scholar Rock in a report on Friday, August 7th. Wedbush reaffirmed an “outperform” rating and set a $58.00 price objective on shares of Scholar Rock in a report on Monday, August 10th. JPMorgan Chase & Co. increased their target price on Scholar Rock from $56.00 to $63.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Finally, Barclays boosted their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Scholar Rock currently has a consensus rating of “Buy” and an average price target of $57.71.

Insider Transactions at Scholar Rock

In related news, Director Joshua Reed sold 3,053 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the sale, the director directly owned 19,518 shares of the company’s stock, valued at approximately $1,048,897.32. This trade represents a 13.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kristina Burow sold 3,053 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the transaction, the director owned 114,657 shares of the company’s stock, valued at approximately $6,161,667.18. The trade was a 2.59% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 17,149 shares of company stock valued at $923,108. Company insiders own 10.30% of the company’s stock.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK opened at $54.72 on Wednesday. The company has a market capitalization of $6.66 billion, a price-to-earnings ratio of -15.86 and a beta of 0.69. Scholar Rock Holding Corporation has a 12 month low of $27.07 and a 12 month high of $58.49. The firm’s 50-day moving average is $51.15 and its 200 day moving average is $48.26. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.84). During the same quarter in the prior year, the company posted ($0.98) earnings per share. Research analysts predict that Scholar Rock Holding Corporation will post -3.24 EPS for the current year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).